pharma · Acute Myeloid Leukemias · Breast Cancer
Syndax Pharmaceuticals
Syndax Pharmaceuticals clinical programs — 29 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 730 3rd Ave, Floor 9, New York, NY 10017, US
- Employees
- 325
- Programs
- 47
- Drugs
- 29
- Patents
- 6
Syndax Pharmaceuticals projects
29 ClinicalTrials.gov programs sponsored by Syndax Pharmaceuticals.
Syndax Pharmaceuticals has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AXATILIMAB
Syndax Pharmaceuticals
Chronic graft versus host disease (cGVHD)
1 trial -
AXATILIMAB, Placebo
Syndax Pharmaceuticals
Idiopathic pulmonary fibrosis
1 trial -
Atezolizumab
Syndax Pharmaceuticals
Metastatic Cancer
1 trial -
Axatilimab
Syndax Pharmaceuticals
Idiopathic Pulmonary Fibrosis
1 trial -
Axatilimab
Syndax Pharmaceuticals
Chronic Graft-versus-host-disease
2 trials -
Azacitidine
Syndax Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
Durvalumab
Syndax Pharmaceuticals
Unresectable Intrahepatic Cholangiocarcinoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Non-Small-Cell Lung Carcinoma
1 trial -
Entinostat
Syndax Pharmaceuticals
ER+ Breast Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals
Hodgkin's Lymphoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Lymphoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Melanoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Metastatic Cholangiocarcinoma
1 trial -
Entinostat
Syndax Pharmaceuticals
Non Small Cell Lung Cancer
2 trials -
Entinostat
Syndax Pharmaceuticals
Renal Cell Carcinoma
2 trials -
Fulvestrant
Syndax Pharmaceuticals
Breast Cancer
1 trial -
Pembrolizumab
Syndax Pharmaceuticals
Bladder Cancer
1 trial -
Pembrolizumab
Syndax Pharmaceuticals
Metastatic Uveal Melanoma
1 trial -
Revumenib
Syndax Pharmaceuticals
Relapsed Adult AML
1 trial -
Revumenib
Syndax Pharmaceuticals
Acute Myeloid Leukemia
2 trials -
Revumenib
Syndax Pharmaceuticals
Colorectal Cancer
1 trial -
Revumenib
Syndax Pharmaceuticals
Leukemia
1 trial -
SNDX-5613
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
SNDX-5613-0700
Syndax Pharmaceuticals
Relapsed or Refractory Acute Leukemias
1 trial -
SNDX-6352
Syndax Pharmaceuticals
Coronavirus
1 trial -
Venetoclax
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
entinostat
Syndax Pharmaceuticals
Breast Cancer
4 trials -
entinostat
Syndax Pharmaceuticals
Epithelial Ovarian Cancer
1 trial -
entinostat
Syndax Pharmaceuticals
Estrogen Receptor-negative Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Syndax Pharmaceuticals have?
29 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.